GoodRx (GDRX) Insider Scott Wagner Buys 73,434 Shares
Scott Wagner bought 73,434 shares of GoodRx Holdings, Inc. on June 16, 2026, as the stock trades at $2.61.
Reviewed by automated data checks against the source filing. How we make and check alerts
Scott Wagner bought 73,434 shares of GoodRx Holdings, Inc. ($GDRX) on June 16, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $GDRX is down 2.2% after 1 week, up 14.3% after 1 month and up 23.1% to date (from the $2.73 close on Jun 16, 2026).
GDRX
GoodRx Holdings, Inc.
Key Points
- Scott Wagner purchased 73,434 shares of GoodRx Holdings, Inc. on June 16, 2026, at a price of $2.61 per share, totaling approximately $191,000.
- GoodRx has seen various insider purchases recently, with multiple executives acquiring the same number of shares on the same day, indicating strong insider confidence.
- Analysts maintain a mixed outlook on GoodRx, with price targets ranging from $4.00 to $5.00, as the company prepares for its next earnings report on November 3, 2026.
Get $GDRX trade alerts by text
We text you when insiders, Congress or big funds trade $GDRX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated GoodRx Holdings, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at GoodRx Holdings, Inc.
Scott Wagner bought 73,434 shares of GoodRx Holdings, Inc. (GDRX) on June 16, 2026, for about $191,000, based on the trading price of $2.61. This purchase adds to a series of insider transactions on the same date, reflecting a notable confidence among company leaders.
Other Executives Join the Buying Spree
On June 16, 2026, several other insiders at GoodRx also bought 73,434 shares each. These insiders include Trevor Bezdek, Agnes Rey-Giraud, Ronald Bruehlman, Kelly Kennedy, and Hirsch Douglas Joseph. Each of these transactions signals a collective belief in GoodRx's future, as they all acquired shares at the same price.
Stock Performance and Current Position
GoodRx's stock is currently trading at $2.61, which is above its 52-week low of $1.77 but below its high of $5.81. The stock's performance in this range may reflect investor sentiment as the company prepares for its next earnings report on November 3, 2026. The recent insider purchases could suggest a belief that the stock is undervalued at this price level.
Analysts Set New Price Targets
Analysts have mixed views on GoodRx. On August 21, 2026, Barclays maintained an Underweight rating with a target price of $4.00. Meanwhile, Citigroup and TD Cowen both maintained Buy ratings with targets of $5.00 on August 11, 2026. UBS also kept a Neutral rating, raising its target to $3.75 on August 13, 2026. This range of opinions reflects differing expectations about GoodRx's performance going forward.
What GoodRx Holdings, Inc. Does
GoodRx Holdings, Inc. provides a platform for consumers to compare prices on prescription drugs. It offers various healthcare services, including telehealth options through its GoodRx Care platform. The company's recent insider activity suggests leaders are optimistic about its performance as it navigates the healthcare landscape.
What's Next for GoodRx
Looking ahead, investors will be watching for GoodRx's next earnings report on November 3, 2026. The recent insider buying indicates confidence from executives, but analysts' mixed ratings highlight the uncertainty in the stock's future performance. Remember, the insider transactions reflect positions as of June 16, 2026, and may not represent current holdings.
Related Filing Alerts
Source: Scott Wagner's Form 4 filing on $GDRX (Jun 16, 2026). Find the original filing: GDRX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts